Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SC vs IV tislelizumab plus chemotherapy in first-line advanced gastric/GEJ cancer
jRCT2031250156Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by BeOne Medicines. Primary endpoints: Model-predicted trough serum concentration (Ctrough) at steady state and Model-predicted AUC0-21d of Cycle 1. Started Sep 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250156.